S
Solu Therapeutics
Solu Therapeutics is a precision-medicine company developing therapeutics to eliminate disease-driving cells
About Solu Therapeutics
Solu Therapeutics is a cutting-edge precision medicine company specializing in the development of therapies aimed at eradicating disease-causing cells. The company operates in the oncology sector, focusing on creating next-generation treatments for cancer patients. Solu Therapeutics leverages advanced scientific techniques to target and eliminate specific cells that drive the progression of various cancers, offering a more personalized and effective approach to treatment.
The primary clients of Solu Therapeutics are healthcare providers, including hospitals, cancer treatment centers, and specialized clinics that treat patients with cancer. The company also collaborates with research institutions and pharmaceutical companies to advance its therapeutic programs.
Solu Therapeutics operates in the highly specialized and competitive market of precision oncology. This market is characterized by the use of detailed genetic and molecular information to tailor treatments to individual patients, thereby increasing the efficacy and reducing the side effects of cancer therapies.
The business model of Solu Therapeutics revolves around the research, development, and commercialization of its therapeutic products. The company invests heavily in clinical trials and regulatory approvals to bring its innovative treatments to market. Revenue is generated through the sale of these therapies to healthcare providers and through partnerships and licensing agreements with other pharmaceutical companies.
In summary, Solu Therapeutics is at the forefront of precision oncology, developing advanced therapies to combat cancer by targeting disease-driving cells. The company serves healthcare providers and operates in the precision medicine market, making money through the commercialization of its treatments and strategic partnerships.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- Boston, United States
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 81.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Apr 2025 | $41M | $164M | Pappas Capital · Longwood Fund · Alexandria Venture Investments · Eli Lilly | ↗ |
| SEEDOther financing | Aug 2023 | $31M | $124M | Astellas Venture · DCVC Bio · Longwood Fund · Sante Ventures | ↗ |
Growth signals
Latest recorded traffic for Solu Therapeutics is 640 monthly website visits, down 50.8% over the last three months. Solu Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Astellas Venture
DCVC Bio
Longwood Fund
Sante Ventures
Alexandria Venture Investments
Series A5 investors entered at this stage
Pappas Capital
Eli Lilly
Hengdian Group
The Leukemia & Lymphoma Society
Biovision Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Solu Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Solu Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.